Compare AMR & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AMR | IOVA |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 968.6M |
| IPO Year | N/A | N/A |
| Metric | AMR | IOVA |
|---|---|---|
| Price | $183.27 | $2.21 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 12 |
| Target Price | ★ $168.00 | $10.36 |
| AVG Volume (30 Days) | 252.3K | ★ 9.8M |
| Earning Date | 11-06-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,226,356,000.00 | $250,425,000.00 |
| Revenue This Year | N/A | $60.94 |
| Revenue Next Year | $17.77 | $60.85 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 175.62 |
| 52 Week Low | $97.41 | $1.64 |
| 52 Week High | $233.20 | $8.56 |
| Indicator | AMR | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 59.93 | 46.56 |
| Support Level | $170.13 | $2.18 |
| Resistance Level | $185.77 | $2.32 |
| Average True Range (ATR) | 8.79 | 0.12 |
| MACD | 2.35 | -0.01 |
| Stochastic Oscillator | 79.71 | 18.11 |
Alpha Metallurgical Resources Inc is a Tennessee-based coal mining company with operations across Virginia and West Virginia. The company's portfolio of mining operations consists of underground mines, surface mines, and coal preparation plants. It produces low-ash metallurgical coal, including High-Vol. A, Mid-Vol., High-Vol. B, and Low-Vol. coal, which is shipped to domestic and international coke and steel producers. The reportable segment of the company is Met. It extracts, processes and markets met and thermal coal from deep and surface mines for sale to steel and coke producers, industrial customers, and electric utilities.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. its objective is to be the leader in innovating, developing, and delivering tumor-infiltrating lymphocyte, or TIL, therapies for patients with solid tumor cancers.